Replies to post #250550 on Biotech Values

[DewDiligence]

Since VRUS in 2011, GILD’s M&A track record is middling at best.

[dewophile]

oral remdesivir update from yesterday:

Announced that the Phase 3 OAKTREE trial of obeldesivir in non-hospitalized participants without risk factors for developing severe COVID-19 did not meet its primary endpoint of improvement in time to symptom alleviation.

https://www.gilead.com/news-and-press/press-room/press-releases/2024/2/gilead-sciences-announces-fourth-quarter-and-full-year-2023-financial-results